Loading
A phase 3 trial of Izalontamab brengitecan, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) is a phase 3 interventional study registered as NCT07640789 by Sichuan Baili Pharmaceutical Co., Ltd., with 418 participants planned, started 2026-08-28 and due to reach its primary completion in 2030-12. Interventions recorded: BL-B01D1, Osimertinib. Conditions listed: Non-small Cell Lung Cancer Stage III. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/